中药药理与临床2025，Vol.41Issue(8)：63-66,4.
S-烯丙基巯基半胱氨酸通过调节Caspase 3/GSDME通路改善顺铂诱导的肾小管上皮细胞损伤
S-Allylmercaptocysteine(SAMC)Improves Cisplatin-Induced Renal Tubular Epithelial Cell Injury by Regulating the Caspase 3/Gasdermin E(GSDME)Pathway
摘要
Abstract
Objective:To explore the mechanism of S-allylmercaptocysteine(SAMC)in improving cisplatin-induced injury in human renal tubular epithelial cells(HK-2)through the caspase 3/gasdermin E(GSDME)pathway.Methods:HK-2 cell activity was measured using the CCK-8 assay.Changes in cell pyroptosis morphology were observed by transmission electron microscopy.The levels of lactate dehydrogenase(LDH),interleukin-1β(IL-1β),and interleukin-18(IL-18)in the cell culture supernatant were determined using LDH and ELISA kits,re-spectively.Hoechst 33342/PI staining was performed to evaluate the percentage of PI-positive HK-2 cells.Caspase 3 and GSDME protein ex-pression levels in the cells were detected by Western blot.Results:Compared to the control group,the model group showed reduced cell via-bility and evident pyroptosis changes observed by electron microscopy.The levels of LDH,IL-1β,IL-18,and the percentage of PI-positive cells were significantly increased,with upregulation of cleaved Caspase 3 and GSDME-N protein expression(P<0.05 or P<0.01).Compared with the model group,SAMC effectively improved cisplatin-induced HK-2 cell injury,reduced the levels of LDH,IL-1β,and IL-18,and de-creased the percentage of PI-positive cells.SAMC also downregulated the protein expression of cleaved Caspase 3 and GSDME-N.Conclu-sion:SAMC improves cisplatin-induced HK-2 cell injury by inhibiting the Caspase 3/GSDME pathway-mediated pyroptosis.关键词
S-烯丙基巯基半胱氨酸/细胞焦亡/焦孔素E/顺铂/HK-2细胞Key words
S-allylmercaptocysteine/Pyroptosis/Gasdermin E/Cisplatin/HK-2 cells引用本文复制引用
朱晓松,王丽萍,孙志清,姜晓燕,袁淑清,彭善鑫,宋庆鑫..S-烯丙基巯基半胱氨酸通过调节Caspase 3/GSDME通路改善顺铂诱导的肾小管上皮细胞损伤[J].中药药理与临床,2025,41(8):63-66,4.基金项目
山东省自然科学基金资助项目(编号:ZR2020QH332、ZR2019BH058、ZR2020QH114) （编号:ZR2020QH332、ZR2019BH058、ZR2020QH114）
国家自然科学基金资助项目(编号:82003435、81903718) （编号:82003435、81903718）
山东省中医药科技发展计划面上项目(编号:2021M020). （编号:2021M020）
